Publication: Immunotherapies for Malignant Glioma
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Boussiotis, Vassiliki A., and Alain Charest. 2017. “Immunotherapies for Malignant Glioma.” Oncogene 37 (9): 1121-1141. doi:10.1038/s41388-017-0024-z. http://dx.doi.org/10.1038/s41388-017-0024-z.
Research Data
Abstract
Glioblastoma Multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.
Description
Other Available Sources
Keywords
glioblastoma, immunotherapy, tumor microenvironment, standard of care
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service